IMNM:NASDAQImmunome, Inc. Analysis
Data as of 2026-04-10 - not real-time
$21.64
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Immunome (IMNM) is trading at $21.64, comfortably above its 20‑day SMA (≈$20.9) but below the 50‑day SMA (≈$22.1), indicating a short‑term pullback within a neutral trend. The RSI sits near 52, the MACD shows a bullish crossover (positive line, negative signal, bullish histogram), and price is holding between a clear support at $19.16 and resistance at $23.14, suggesting limited downside and upside potential toward the analyst median target of $36.
Fundamentally, the company reports minimal revenue ($6.9 M) and deep operating losses, yet it sits on a massive cash pile of $653 M and modest debt, providing a runway for its Phase 3 Varegacestat trial and early‑stage ADC programs. However, high 30‑day volatility (~56 %), a beta near 2, decreasing volume, and recent insider sales add considerable risk, while the biotech sector’s regulatory uncertainty remains elevated.
Fundamentally, the company reports minimal revenue ($6.9 M) and deep operating losses, yet it sits on a massive cash pile of $653 M and modest debt, providing a runway for its Phase 3 Varegacestat trial and early‑stage ADC programs. However, high 30‑day volatility (~56 %), a beta near 2, decreasing volume, and recent insider sales add considerable risk, while the biotech sector’s regulatory uncertainty remains elevated.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD crossover within a tight trading range
- Recent insider sell adds short‑term pressure
- High volatility and decreasing volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Large cash reserve supports continued R&D
- Phase 3 trial progress could unlock significant upside
- Analyst consensus strong‑buy with ~64% upside potential
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Potential blockbuster revenue from successful oncology ADCs
- Strong balance sheet mitigates cash‑burn concerns
- Long‑term market sentiment reflected by extreme‑greed index
Key Metrics & Analysis
Financial Health
Revenue Growth-100.00%
P/E Ratio-10.2
ROE-52.09%
ROA-28.98%
Debt/Equity0.61
P/B Ratio3.9
Op. Cash Flow$-190919008
Free Cash Flow$-133619624
Industry P/E26.1
Technical Analysis
TrendNeutral
RSI51.7
Support$19.16
Resistance$23.14
MA 20$20.92
MA 50$22.12
MA 200$16.53
MACDBullish
VolumeDecreasing
Fear & Greed Index87.68
Valuation
Target Price$35.54
Upside/Downside64.23%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.96
Volatility56.60%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.